Canada’s Alberta confirms first death linked to AstraZeneca vaccine By Reuters

0
10

© Reuters. FILE PHOTO: Vials labelled “AstraZeneca COVID-19 Coronavirus Vaccine” and a syringe are seen in front of a displayed AstraZeneca logo in this illustration taken March 10, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) -The Canadian province of Alberta reported its first death of a patient from a rare blood clot condition after receiving the AstraZeneca (NASDAQ:) COVID-19 vaccine, its chief medical officer confirmed late Tuesday.

The Alberta case marks the second case of blood clots, and the only death after more than 253,000 doses of AstraZeneca were administered in the province, the statement added.

AstraZeneca did not immediately respond to Reuters’ request for a comment.

Last month, the province of Quebec reported Canada’s first death of a patient after receiving the AstraZeneca COVID-19 vaccine.

The rare complication, which some regulators including Health Canada are calling Vaccine-Induced Prothrombotic Immune Thrombocytopenia, involves blood clots accompanied by a low count of platelets, cells in the blood that help it to clot.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.